GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Imunon Inc (LTS:0HUZ) » Definitions » Marketable Securities

Imunon (LTS:0HUZ) Marketable Securities : $0.00 Mil (As of Mar. 2025)


View and export this data going back to 2018. Start your Free Trial

What is Imunon Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Imunon's Marketable Securities for the quarter that ended in Mar. 2025 was $0.00 Mil.

Imunon's annual Marketable Securities declined from Dec. 2022 ($21.25 Mil) to Dec. 2023 ($9.86 Mil) and declined from Dec. 2023 ($9.86 Mil) to Dec. 2024 ($0.00 Mil).


Imunon Marketable Securities Historical Data

The historical data trend for Imunon's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Imunon Marketable Securities Chart

Imunon Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 29.80 21.25 9.86 -

Imunon Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.46 - - - -

Imunon Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Imunon  (LTS:0HUZ) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".


Imunon Marketable Securities Related Terms

Thank you for viewing the detailed overview of Imunon's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Imunon Business Description

Traded in Other Exchanges
Address
997 Lenox Drive, Suite 100, Lawrenceville, NJ, USA, 08648
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).

Imunon Headlines

No Headlines